Condition: SPINAL Fracture · Burst Fracture · Spinal Instability of Thoracolumbar Region · Sponsor: Insel Gruppe AG, University Hospital Bern
Treatment for acute traumatic thoracolumbar burst fractures differs significantly across the world in patients without neurological impairments and without damage to the posterior column of the spine. This randomized controlled, non-inferiority clinical trial's goal is to evaluate the effectiveness of surgery versus initial non-surgical treatment for patients with traumatic thoracolumbar spine burst fractures who don't have any neurological symptoms. The study's precise objectives are to: 1. evaluate the clinical outcome (Oswestry Disability Index) 2. evaluate the radiography result (restoration and maintenance of spinal alignment) 3. determine the prevalence of complications at least 24 months of follow-up of neurologically unaffected patients with acute traumatic burst fractures. Both groups will get the same therapy using standardized methods: The surgical group's entire patient population will get combined anterior-posterior (360°) spinal fusion therapy. Three-point hyperextension orthoses will be used to treat all patients in the non-surgical group for six weeks following the injury.
This description comes directly from the study's public registry record.
Christoph E Albers, PD Dr. · +41 (0) 31 664 04 40 · christoph.albers@insel.ch
Sonja Häckel, Dr. · +41 (0) 31 664 04 40 · sonja.haeckel@insel.ch
Always discuss trial participation with your own doctor first.
| Inselspital | Bern, Switzerland | Recruiting |
| Ostschweizer Wirbelsaeulenzentrum Kantonsspital St. Gallen | Sankt Gallen, Switzerland | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05769114